z-logo
Premium
Glucose insulin potassium infusion improves systolic function in patients with chronic ischemic cardiomyopathy
Author(s) -
Cottin Yves,
Lhuillier Isabelle,
Gilson Laurent,
Zeller Marianne,
Bonnet Caroline,
Toulouse Christine,
Louis Pierre,
Rochette Luc,
Girard Claude,
Wolf JeanEric
Publication year - 2002
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1016/s1388-9842(01)00222-7
Subject(s) - medicine , ejection fraction , cardiology , insulin , hemodynamics , heart failure , cardiomyopathy , cardiac function curve , ischemic cardiomyopathy , diabetes mellitus , endocrinology
Objective: We assessed the effects of glucose–insulin–potassium (GIK) by echocardiography in stable patients with ischemic dysfunction. Methods: Twelve male patients with stable coronary disease (SCD) and ejection fraction (EF) <45% were studied for systolic function. GIK (glucose 30%, 300 insulin units and KCl 6 g/l) was infused at 1 ml/kg per h over 20 min. Hemodynamic and echocardiographic measurements were recorded at rest ( T 0 ), at the end (20 min) of GIK infusion ( T + 20), 20 and 40 min after the end of the infusion ( T + 40 and T + 60). Results: At T + 20, a significant decrease in WMSI (wall motion score index) was observed compared with T 0 (2.16±0.14 vs. 2.30±0.16: P <0.05). An increase in EF was reported at T + 40 and T + 60 compared with T 0 (44.1±7.8% and 53.3±11.6% vs. 35.6±4.5%, respectively: P <0.01). A decrease in WMSI was observed at T + 40 and T + 60 compared with rest (2.02±0.17 and 1.93±0.11 vs. 2.30±0.16, respectively: P <0.01). Conclusion: Our present work suggests that GIK infusion improves systolic function in patients with SCD and ejection fraction <45%. Further studies are needed to determine if short‐term GIK infusion could be useful for therapeutic or diagnostic strategies in these patients.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here